Abstracts tagged "spondyloarthritis"

Abstract Number: 1785 • ACR Convergence 2023
Machine Learning Models Identify Gut Microbiota That Predict Chronicity in Reactive Arthritis
Prakashini MV¹, Soumendu Mahapatra², Krushna Chandra Murmu², Rasmita Mishra², Prasanta Padhan¹, Punit Prasad², Ramnath Misra³ and Sakir Ahmed⁴, ¹Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India, ²Institute of Life Sciences, Bhubaneswar, India, ³Kalinga Institute of Medical Sciences, KIIT University, Lucknow, India, ⁴Kalinga Institute of Medical Sciences, Bhubaneswar, India
Background/Purpose: Reactive arthritis (ReA) is the unique infection-triggered spondyloarthritis (SpA). Undifferentiated peripheral SpA (UpSpA) is similar but without previous infection, or psoriasis or inflammatory bowel…
Abstract Number: 2195 • ACR Convergence 2023
Regional Differences in Clinical Phenotype of Axial Spondyloarthritis. Results from the International Map of Axial Spondyloarthritis (IMAS)
Denis Poddubnyy¹, Fernando Sommerfleck², Victoria Navarro-Compán³, Christine Bundy⁴, Souzi Makri⁵, Shashank Murlidhar Akerkar⁶, Lillann Wermskog⁷, Elie Karam⁸, Jose Correa Fernandez⁹, Asif Siddiqui¹⁰ and Marco Garrido-Cumbrera¹¹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Sanatorio Julio Mendez, Buenos Aires, Argentina, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Cardiff University, Cardiff, United Kingdom, ⁵Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, ⁶Mumbai Arthritis Clinic, Mumbai, India, ⁷Spondyloarthritis Association of Norwary (SPAFO);Axial Spondyloarthritis International Federation (ASIF), Oslo, Norway, ⁸Canadian Spondylitis Association (CSA), Toronto, ON, Canada, ⁹Universidad de Sevilla, Health & Territory Research (HTR), Sevilla, Spain, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹University of Seville, Sevilla, Spain
Background/Purpose: Previous studies have suggested there could be regional differences in clinical phenotype of axial spondyloarthritis (axSpA). This analysis aims to explore differences in axSpA…
Abstract Number: 2213 • ACR Convergence 2023
Identification of a Diagnostic Model for Axial Spondyloarthritis in Daily Clinical Practice Using a Random Forest Machine Learning Approach
Imke Redeker¹, Styliani Tsiami², Jan Eicker³, Uta Kiltz⁴, David Kiefer², Ioana Andreica⁵, Philipp Sewerin² and Xenofon Baraliakos⁶, ¹Ruhr Universität Bochum, Bochum, Germany, ²Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ³Rheumazentrum Ruhrgebiet Herne and Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: In axial spondyloarthritis (axSpA), early diagnosis plays a key role in preventing disease progression. However, a validated diagnostic algorithm does not exist, while classification…
Abstract Number: 2545 • ACR Convergence 2023
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study
Atul Deodhar¹, Jerzy Supronik², Alan Kivitz³, Guillermo Valenzuela⁴, Karen Kapur⁵, Susanne Rohrer⁶, Eva Dokoupilova⁷, Hanno Richards⁶ and Karel Pavelka⁸, ¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ²OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, ⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: While subcutaneous secukinumab (SEC) is approved for the treatment of axial spondyloarthritis (axSpA), some patients may benefit more from intravenous (IV) administration. This study…
Abstract Number: 0506 • ACR Convergence 2023
Patient and Physician Global Assessment of Psoriatic Arthritis Disease Activity: High Concordance in an ArLAR Multinational Study
Nelly Ziade¹, Noura Abbas², Lina El Kibbi³, Avin Maroof⁴, Bassel Elzorkany⁵, Nizar Ani⁶, ASAL ADNAN⁷, NABAA IHSAN JAWAD AWADH⁷, Faiq Gorial⁸, Nada Alchama⁹, Chafika Haouichat¹⁰, Fatima Alnaimat¹¹, Suad Hannawi¹², Saed Atawnah¹³, HUSSEIN HALABI¹⁴, Manal Al-Mashaleh¹⁵, Laila Aljazwi¹⁶, Ahmed Abogamal¹⁷, laila Ayoub¹⁸, Elyes Bouajina¹⁹, Rachid Bahiri²⁰, Sahar Saad²¹, Maha Sabkar²¹, Krystel Aouad²², Laure Gossec²³ and Ihsane Hmamouchi²⁴, ¹Saint-Joseph University, Beirut, Lebanon, ²Saint Joseph University Beirut, Beirut, Lebanon, ³Specialized Medical Center, Riyadh, Saudi Arabia, ⁴Kurdistan University Hawler, Erbil, Iraq, ⁵Private (BZRC), Cairo, Egypt, ⁶Baghdad College of Medicine, Baghdad, Iraq, ⁷Baghdad Teaching Hospital, Baghdad, Iraq, ⁸University of Baghdad, Baghdad, Iraq, ⁹Ebn Al Nafiss Hospital, Damascus, Syria, ¹⁰Faculty of Medicine El Mahdi Si Ahmed, Blida, Algeria, ¹¹University of Jordan, Amman, Jordan, ¹²Kuwait Hospital, Department of Rheumatology, Dubai, United Arab Emirates, ¹³Al ahli hospital, Hebron, Palestine, Hebron, Palestinian Territories, ¹⁴King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia, ¹⁵Royal Medical Services, Amman, Jordan, ¹⁶Tripoli, Tripoli, Libya, ¹⁷Saudi German Hospital Dubai, Dubai, United Arab Emirates, ¹⁸University of Tripoli, Tripoli, Libya, ¹⁹Farhat Hached Hospital of Sousse, Sousse, Tunisia, ²⁰Department of Rheumatology, El Ayachi Hospital Medical University, Sale, Morocco, ²¹King Hamad University Hospital, Bahrain, Bahrain, ²²Saint George Hospital University Medical Center, Beirut, Lebanon, ²³Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ²⁴Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Morocco
Background/Purpose: In patients with psoriatic arthritis (PsA), discordance between physicians and patients when assessing disease activity has been described as frequent, mainly in European and…
Abstract Number: 0534 • ACR Convergence 2023
Tapering Tofacitinib for Axial Spondyloarthritis in Remission or Low-disease Activity State
Pankti Mehta¹, Sanjo Saijan², Justin George², Sakir Ahmed³, Bhowmik Meghnathi⁴ and Padmanabha Shenoy², ¹King George's Medical University, Mumbai, India, ²Centre for arthritis and rheumatism excellence, Kochi, India, ³Kalinga Institute of Medical Sciences, Bhubaneswar, India, ⁴Smt. NHL Municipal Medical College and SVP hospital, CIMS Hospital, Ahmedabad, India
Background/Purpose: The recent recommendations from EULAR-ASAS for Axial Spondyloarthritis (AxSpA) call for decreasing biologic (b)DMARDs after an extended period of remission. This is especially relevant…
Abstract Number: 1038 • ACR Convergence 2023
Improved Assessment of Structural Damage in the Spine in Patients with Axial Spondyloarthritis by MRI-based Synthetic CT: A Comparison with Low-dose CT and X-ray
Simone Tromborg Willesen¹, Nora Vladimirova¹, Jakob Moeller², Anna Enevold Fløistrup Hadsbjerg¹, Bimal Mayur Kumar Vora³, Sengul Seven¹, Susanne Juhl Pedersen¹ and Mikkel Østergaard¹, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ²Herlev-Gentofte Hospital, Herlev, Denmark, ³Singapore General Hospital, Singapore, Singapore
Background/Purpose: Whether a therapy has bone structure-modifying effects in the spine is crucial to determine since this is a prerequisite for a therapy to reduce…
Abstract Number: 1405 • ACR Convergence 2023
Diagnostic Delay of Axial Spondyloarthritis in African American Patients
John Byun¹, Hans Vitzthum von Eckstaedt¹, Kichul Ko² and Reem Jan¹, ¹University of Chicago, Chicago, IL, ²The University of Chicago, Chicago, IL
Background/Purpose: The identification of axial spondyloarthritis (axSpA) remains challenging. The initial presentation is not always immediately apparent as an inflammatory disease, potentially leading to years…
Abstract Number: 1790 • ACR Convergence 2023
Expansion of CD8+ TCRVβ9+ T Cells in the Peripheral Blood of HLA-B27+ Patients with Axial Spondyloarthritis
Caroline Bauchiero¹, Micah Lefton¹, Stephanie Sinnappan², Jeffrey Sparks³ and Joerg Ermann⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Studies in human HLA-B27 transgenic rats largely discredited the idea that CD8+ T cells are key drivers of disease in axial spondyloarthritis (axSpA). However,…
Abstract Number: 2196 • ACR Convergence 2023
Females with Axial Spondyloarthritis Report Higher Burden of Disease and Worse Patient-reported Outcomes. Results from the International Map of Axial Spondyloarthritis (IMAS)
Victoria Navarro-Compán¹, Marco Garrido-Cumbrera², Denis Poddubnyy³, Christine Bundy⁴, Souzi Makri⁵, Jose Correa Fernandez⁶, Shashank Murlidhar Akerkar⁷, Lillann Wermskog⁸, Elie Karam⁹, Asif Siddiqui¹⁰ and Fernando Sommerfleck¹¹, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²University of Seville, Sevilla, Spain, ³Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Cardiff University, Cardiff, United Kingdom, ⁵Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, ⁶Universidad de Sevilla, Health & Territory Research (HTR), Sevilla, Spain, ⁷Mumbai Arthritis Clinic, Mumbai, India, ⁸Spondyloarthritis Association of Norwary (SPAFO);Axial Spondyloarthritis International Federation (ASIF), Oslo, Norway, ⁹Canadian Spondylitis Association (CSA), Toronto, ON, Canada, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Sanatorio Julio Mendez, Buenos Aires, Argentina
Background/Purpose: There is increasing evidence of differences between males and females in axial spondyloarthritis (axSpA), but the source is restricted to specific geographic locations or…
Abstract Number: 2214 • ACR Convergence 2023
Systematic Literature Review and Meta-analysis Informing the Development of 2023 Spondyloarthritis Research and Treatment Network (SPARTAN) Referral Recommendations for Axial Spondyloarthritis
Abhijeet Danve¹, Maureen Dubreuil², Swetha Ann Alexander³, Yuliya afinogenova⁴, Mohamad Bittar⁵, Alyssa Grimshaw⁶, Liana Fraenkel⁷, Michael LaValley⁸, Anand Kumthekar⁹, Jean liew¹⁰, Marina Nighat Magrey¹¹, Vikas Majithia¹², Sali Merjanah¹³, Hillary Norton¹⁴, Jessica A Walsh¹⁵ and Atul Deodhar¹⁶, ¹Yale University School of Medicine, Glastonbury, CT, ²Department of Rheumatology, Boston University School of Medicine, Milton, MA, ³University of Utah Health, Salt Lake City, UT, ⁴Yale, Hamden, CT, ⁵The University of Tennessee Health Science Center, Memphis, TN, ⁶Yale University, New Haven, CT, ⁷Berkshire Health Systems, Lenox, MA, ⁸Boston University School of Public Health, Arlington, MA, ⁹Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ¹⁰Boston University, Boston, MA, ¹¹Case Western Reserve University, University Hospitals, Cleveland, OH, ¹²Mayo Clinic Florida, Jacksonville, FL, ¹³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ¹⁴Inspire Santa Fe Rheumatology, Santa Fe, NM, ¹⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ¹⁶Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Lack of timely referral of suspected axSpA patients to rheumatologists contributes to misdiagnosis, delayed treatment, and poor outcomes. Currently there are no formal guidelines…
Abstract Number: 2547 • ACR Convergence 2023
Characteristics of Difficult-To-Treat Axial Spondyloarthritis: Results of a Multicentric Retrospective Study
Cecile PHILIPPOTEAUX¹, Thibaut DELEPINE², Emeline Cailliau¹, Peggy Philippe¹, Nicolas TAISNE³, Tristan Pascart⁴, Julien Paccou¹, Bernard Cortet¹, Rene-Marc Flipo¹ and Jean-Guillaume Letarouilly⁵, ¹University Hospital Center of Lille, Lille, France, ²CHU de Lille, Lille University Hospital, Valenciennes, France, ³Valenciennes Hospital Center, Valenciennes, France, ⁴Department of Rheumatology, Saint-Philibert Hospital, Lille Catholic University, Lille, France, ⁵CHU Lille, Lille, France
Background/Purpose: The EULAR task force recently published the difficult-to-treat (D2T) RA definition1, however, a definition of D2T axSpA is still lacking. To date, we have…
Abstract Number: L02 • ACR Convergence 2022
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Christopher Ritchlin¹, Laura Coates², Iain McInnes³, Philip J. Mease⁴, Joseph Merola⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Laure Gossec⁸, Alice Gottlieb⁹, Diamant Thaci¹⁰, Barbara Ink¹¹, Deepak Assudani¹¹, Rajan Bajracharya¹¹, Vish Shende¹¹, Jason Coarse¹² and Robert Landewé¹³, ¹University of Rochester Medical Center, Rochester, NY, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ³College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁵Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁶University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁷Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁸Sorbonne Universités, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière, Rheumatology Department, Paris, France, Paris, France, ⁹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹¹UCB Pharma, Slough, United Kingdom, ¹²UCB Pharma, Raleigh, NC, ¹³Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, and Zuyderland MC, Heerlen, Netherlands
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy in joints and…
Abstract Number: L14 • ACR Convergence 2022
Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
Xenofon Baraliakos¹, Atul Deodhar², Désirée van der Heijde³, Marina Magrey⁴, Walter Maksymowych⁵, Tetsuya Tomita⁶, Huji Xu⁷, Marga Oortgiesen⁸, Ute Massow⁹, Carmen Fleurinck¹⁰, Alicia M Ellis⁸, Tom Vaux¹¹, Julie Shepherd-Smith¹¹, Alexander Marten⁹ and Lianne S Gensler¹², ¹Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, ²Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, US, Richfield, OH, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Graduate School of Health Science, Morinomiya University of Medical Science, Osaka City, Osaka City, Osaka, Japan, ⁷Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China (People's Republic), ⁸UCB Pharma, Morrisvile, NC, ⁹UCB Pharma, Monheim am Rhein, Nordrhein-Westfalen, Germany, ¹⁰UCB Pharma, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL‑17A. In the phase 3 BE MOBILE 1 and 2…
Abstract Number: L15 • ACR Convergence 2022
Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study
Xenofon Baraliakos¹, Mikkel Østergaard², Denis Poddubnyy³, Désirée van der Heijde⁴, Atul Deodhar⁵, Pedro M. Machado⁶, Victoria Navarro-Compán⁷, Kay Geert Hermann⁸, Mitsumasa Kishimoto⁹, Eun Young Lee¹⁰, Lianne S Gensler¹¹, Uta Kiltz¹, Marco Eigenmann¹², Patricia Pertel¹³, Aimee Readie¹⁴, Hanno B. Richards¹², Brian Porter¹⁵ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ³Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁶Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁷Department of Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ⁸Department of Radiology, University Hospital Charité - Campus Mitte, Charitéplatz, Berlin, Germany, ⁹Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, ¹¹Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ¹²Novartis Pharma AG, Basel, Switzerland, ¹³Novartis Pharma AG, Reinach, Switzerland, ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁵Novartis Pharmaceuticals Corporation, Far Hills, NJ
Background/Purpose: Biologics are clinically efficacious in patients (pts) with axial spondyloarthritis (axSpA) including radiographic axSpA (r-axSpA). Limited data exist on the effect of biologics in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].